Form D · Biotechnology

Soricimed Biopharma Inc.

Moncton, A3 · CIK 0001532755

Offering snapshot reported Jan 19, 2023 · SEC filing

Reported sold
$2.78M
Offering amount: $3.73M
Investors reported
45
Form D · investor count
Minimum accepted
$7.86K
Reported outside-investor minimum
First sale
Jul 23, 2021
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$1.39M$2.78MJan 31, 2022: $1,414,655.00Jan 31, 2022Jan 19, 2023: $2,775,233.00Jan 19, 2023

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$1,414,655 → $2,775,233
  • Reported investors42 → 45

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 19, 2023Amendment$2,775,233$1,360,578vs Jan 31, 202245SEC filing
Jan 31, 2022Initial$1,414,655No comparison42SEC filing
Oct 18, 2011Initial$109,000No comparison2SEC filing

Offering details

Securities
Equity
Exemptions
06c
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-431623

Source: Form D, filed Jan 19, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Camille Belliveau Director
Robert Bruce Executive
Vaughn Embro Pantelony Director
Paul Gunn Director, Executive
Susan Hicks Director
Tom Reeves Director
Marc Rubin Director
Jack Stewart Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
18 Botsford Street Suite 201
Moncton, A3, E1C 4W7